ADIENNE Pharma & Biotech has entered into a Service Agreement with Selexis for the rapid development of a manufacturing cell line for one of ADIENNE’s orphan drugs .
(PRWeb May 15, 2012)
Read the full story at http://www.prweb.com/releases/human_mini_antibody/Selexis_orphan_drug/prweb9506843.htm